What Management Said
Read the full Q2 2025 transcript ↗This morning, I know you are eager to get into the underlying details of our revised financial outlook, which we will do. John Rex will discuss financial performance and the elements affecting our outlook, and I'll come back with some closing thoughts, and then we'll have ample time for questions and answers. The primary driver of the UnitedHealthcare earnings shortfall for 2025 is that our pricing assumptions were well short of actual medical costs. Our current view for 2025 reflects $6.5 billion more in medical costs than we anticipated in our initial outlook.
In addition to trend-driven issues, the updated 2025 outlook removes about $1 billion from previously planned portfolio actions that we are no longer pursuing. We also believe we can resolve our current issues and recapture our earnings growth potential. On trends specifically, the increase in care activity across individual and group Medicare Advantage we saw earlier this year has now affected complex populations and our Medicare supplement business as well. However, inpatient utilization has accelerated through Q2, and we expect will comprise a relatively larger portion of the pressure over the full year.
In the ACA business, the revenue impact resulting from a difference between the morbidity that we price for and what we experienced is the primary cause of our underperformance. Their trend is approaching 11%, which is approximately 100 basis points higher than our initial expectations. Beyond these segment-specific factors, there are other broad drivers of higher medical cost. There has been a marked increase in healthcare cost due in part to increases in service intensity per encounter.
- Second-quarter revenues were nearly $112 billion, up 13% year-over-year, with growth across both UnitedHealthcare and Optum.
- Optum Rx revenues grew 19% to $38.5 billion and total adjusted scripts rose to 414 million from 399 million a year earlier.
- Optum Insight revenues increased 6% to $4.8 billion, with a contract revenue backlog of $32.1 billion.
- A new leadership team was installed across Optum (Roger Connor, Krista Nelson, Dhivya Suryadevara, John Prince) to drive improved execution.
- The dividend was increased 5% in June.
- The most mature value-based care cohorts (2021 and prior) are operating at 8%+ margins and Optum Health services businesses at roughly 10% margins, supporting the long-term case.
- Adjusted EPS of $4.08 fell below the prior-year period and included about $1.2 billion of discrete items.
- The full-year 2025 outlook was cut to at least $16 adjusted EPS, with the medical care ratio midpoint raised from 86.5% to 89.25%.
- UnitedHealthcare absorbed roughly $6.5 billion more in medical costs than anticipated (~$3.6 billion Medicare, ~$2.3 billion commercial, the remainder Medicaid).
- Optum Health earnings are running approximately $6.6 billion below expectations, with value-based care margins compressed to about 1% versus over 3% in 2024 and nearly 5% in 2023.
- Medical trends spiked well above pricing: MA now ~7.5% versus an initial ~5% assumption, MedSupp over 11%, and Medicaid behavioral trend around 20%.
- The Optum Health long-term margin target was lowered to 6%-8%, and the company will exit MA plans serving over 600,000 members for 2026.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Adjusted EPS | FY2025 | at least $16 (lowered) |
| Revenues | FY2025 | approaching $448 billion (+11%) |
| Medical care ratio | FY2025 | 89.25% ±25 bps (raised) |
| Effective tax rate | FY2025 | ~18.5% |
| Cash flow from operations | FY2025 | ~$16 billion (1.1x net income) |
| MA medical cost trend | FY2025 | ~7.5% (raised) |
| MA pricing trend | FY2026 | approaching 10% |
| Optum Health long-term margin | long-term | 6%-8% (lowered) |
| 2026 earnings growth | FY2026 | solid but moderate, accelerating in 2027 |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Revenues | +13% to nearly $112 billion | growth across UnitedHealthcare and Optum |
| Adjusted EPS | $4.08, below prior year | pricing and medical cost trend factors at UnitedHealthcare and Optum Health plus ~$1.2 billion of discrete items |
| UnitedHealthcare operating earnings | -$1.9 billion to $2.1 billion | medical trend factors including a ~$600 million ACA premium deficiency reserve |
| Optum Health revenues | -$1.8 billion to $25.2 billion | prior contract adjustments and Medicare funding reductions |
| Optum Rx revenues | +19% to $38.5 billion | new customer adds and continued specialty product contribution |
| Optum Insight revenues | +6% to $4.8 billion | post-cyber customer recovery, pacing slower than expected |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Medical cost trend | ~5% MA assumption at bid | ~7.5% MA, over 11% MedSupp, ~20% Medicaid behavioral | Sharply elevated |
| Optum Health value-based care | growth focus | $6.6 billion below plan; refocus to original intent; 6%-8% target | Reset |
| Pricing and margin recovery | — | 2026 priced at ~10% MA trend with intense margin-recovery focus | Corrective |
| Leadership and culture reform | — | extensive management changes, humility, transparency, independent reviews (Analysis Group, FTI) | Overhaul |
| Capital and M&A | — | balanced capital use, pending Amedisys, 5% dividend increase | Cautious |
| V28 risk-model transition | — | estimated $11 billion three-year headwind, ~$4 billion remaining in 2026 with about half to be offset | Headwind |
Q&A Summary
More on Unitedhealth Group Inc
See how Top Bucket AI works for your firm
Request DemoStay ahead of private markets
Research and market intelligence for private-markets professionals.
You're subscribed.
Thanks for signing up.